GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CuraScientific Corp (OTCPK:CSTF) » Definitions » Cash-to-Debt

CuraScientific (CuraScientific) Cash-to-Debt : 0.06 (As of Sep. 2023)


View and export this data going back to . Start your Free Trial

What is CuraScientific Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. CuraScientific's cash to debt ratio for the quarter that ended in Sep. 2023 was 0.06.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, CuraScientific couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for CuraScientific's Cash-to-Debt or its related term are showing as below:

CSTF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0   Med: 0.02   Max: 0.48
Current: 0.06

During the past 3 years, CuraScientific's highest Cash to Debt Ratio was 0.48. The lowest was 0.00. And the median was 0.02.

CSTF's Cash-to-Debt is ranked worse than
89.79% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.94 vs CSTF: 0.06

CuraScientific Cash-to-Debt Historical Data

The historical data trend for CuraScientific's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

CuraScientific Cash-to-Debt Chart

CuraScientific Annual Data
Trend Dec20 Dec21 Dec22
Cash-to-Debt
0.02 0.02 -

CuraScientific Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.48 0.06

Competitive Comparison of CuraScientific's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, CuraScientific's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CuraScientific's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CuraScientific's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where CuraScientific's Cash-to-Debt falls into.



CuraScientific Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

CuraScientific's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

CuraScientific's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CuraScientific  (OTCPK:CSTF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


CuraScientific Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of CuraScientific's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


CuraScientific (CuraScientific) Business Description

Traded in Other Exchanges
N/A
Address
51544 Cesar Chavez Street, Suite No. 1J, Coachella, CA, USA, 92236
CuraScientific Corp manufactures commercial chemicals with a variety of commercial sterilization applications for agriculture, warehousing, hospitality, and medical facilities. The company's product, DiOx+, is a disinfectant sterilizer that kills harmful pathogens without exposing people or the environment to dangerous toxins.
Executives
Paul Quentin Goyette director 2205 LOCH WAY, EL DORADO HILLS CA 95762
William Joseph Reed director, officer: Chief Executive Officer 333 N UNIVERSITY AVE., #33, REDLANDS CA 92374
Johann Loewen director C/O METHES ENERGIES INTERNATIONAL LTD, 3651 LINDELL ROAD, SUITE D-272, LAS VEGAS NV 89103
Edouard Maurice Beaudette director 13480 N BLOOMFIELD ROAD, NEVADA CITY CA 95959
Justin Michael Gonzalez director, officer: Chief Executive Officer 15723 LAKE VERA PURDON RD., NEVADA CITY CA 95959
Eric Jason Watson director, officer: Chief Operating Officer 19553 BOWERS DRIVE, TOPANGA CA 90290

CuraScientific (CuraScientific) Headlines

From GuruFocus

Introducing Leaf of Faith

By Marketwired Marketwired 03-26-2019